RXFP1 and Myocardial fibrosis: Studies on diseases such as myocardial fibrosis have shown that RLX‐2 can inhibit endothelial cell transformation into mesenchymal cells by activating the RXFP1/eNOS/NO pathway, thereby downregulating TGF‐β1/Smad/CTGF signaling and exerting antifibrotic effects.41